EA201691029A1 - Кристаллические формы аналогов противовирусного соединения софосбувира - Google Patents
Кристаллические формы аналогов противовирусного соединения софосбувираInfo
- Publication number
- EA201691029A1 EA201691029A1 EA201691029A EA201691029A EA201691029A1 EA 201691029 A1 EA201691029 A1 EA 201691029A1 EA 201691029 A EA201691029 A EA 201691029A EA 201691029 A EA201691029 A EA 201691029A EA 201691029 A1 EA201691029 A1 EA 201691029A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compound
- antogovirus
- sofosbuvir
- analogues
- crystal forms
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000013078 crystal Substances 0.000 title 1
- TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 title 1
- 229960002063 sofosbuvir Drugs 0.000 title 1
- -1 -isopropyl ester Chemical class 0.000 abstract 2
- 241000711549 Hepacivirus C Species 0.000 abstract 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 abstract 1
- 235000019260 propionic acid Nutrition 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Описаны кристаллические твердые формы соединения (S)-изопропиловый эфир 2-((S)-(((2R,3R,4R,5R)-5-(2,4-диоксо-3,4-дигидропиримидин-1(2Н)-ил)-4-фтор-3-гидрокси-4-метилтетрагидрофуран-2-ил)метокси)(фенокси)фосфориламино)пропановой кислоты (соединение I)применяемые против вируса гепатита С. Согласно настоящему изобретению также предложены способы получения и способы применения указанных кристаллических форм.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361920371P | 2013-12-23 | 2013-12-23 | |
PCT/US2014/069123 WO2015099989A1 (en) | 2013-12-23 | 2014-12-08 | Crystalline forms of antiviral sofosbuvir analogues |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201691029A1 true EA201691029A1 (ru) | 2017-01-30 |
Family
ID=52146765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201691029A EA201691029A1 (ru) | 2013-12-23 | 2014-12-08 | Кристаллические формы аналогов противовирусного соединения софосбувира |
Country Status (27)
Country | Link |
---|---|
US (1) | US9340568B2 (ru) |
EP (1) | EP3086795A1 (ru) |
JP (1) | JP2017503015A (ru) |
KR (1) | KR20160099710A (ru) |
CN (1) | CN105873593A (ru) |
AP (1) | AP2016009254A0 (ru) |
AR (1) | AR098929A1 (ru) |
AU (1) | AU2014370299B2 (ru) |
BR (1) | BR112016013714A8 (ru) |
CA (1) | CA2934799A1 (ru) |
CL (1) | CL2016001509A1 (ru) |
CR (1) | CR20160288A (ru) |
CU (1) | CU20160096A7 (ru) |
DO (1) | DOP2016000141A (ru) |
EA (1) | EA201691029A1 (ru) |
HK (1) | HK1222334A1 (ru) |
IL (1) | IL246066A0 (ru) |
MD (1) | MD20160087A2 (ru) |
MX (2) | MX2016008453A (ru) |
MY (1) | MY178102A (ru) |
PE (1) | PE20160750A1 (ru) |
PH (2) | PH12019500372A1 (ru) |
SG (1) | SG11201604818SA (ru) |
TW (1) | TW201609785A (ru) |
UY (1) | UY35917A (ru) |
WO (1) | WO2015099989A1 (ru) |
ZA (1) | ZA201604345B (ru) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2345659A1 (en) | 2003-05-30 | 2011-07-20 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
SI3845221T1 (sl) | 2014-06-13 | 2024-03-29 | Ratiopharm Gmbh | Trdne oblike sofosbuvirja |
WO2016023906A1 (en) * | 2014-08-13 | 2016-02-18 | Sandoz Ag | A crystalline form of sofosbuvir |
KR20230130175A (ko) | 2014-12-26 | 2023-09-11 | 에모리 유니버시티 | N4-하이드록시시티딘, 이와 관련된 유도체 및 이의 항 바이러스적 용도 |
WO2016156512A1 (en) * | 2015-04-01 | 2016-10-06 | Sandoz Ag | A process for preparing a crystalline form of sofosbuvir |
WO2017023716A1 (en) * | 2015-08-04 | 2017-02-09 | Merck Sharp & Dohme Corp. | Fixed-dose combinations of antiviral compounds |
US20180228827A1 (en) * | 2015-08-04 | 2018-08-16 | Merck Sharp & Dohme Corp. | Fixed-dose combinations of antiviral compounds |
WO2017023714A1 (en) * | 2015-08-04 | 2017-02-09 | Merck Sharp & Dohme Corp. | Fixed-dose combinations of antiviral compounds |
WO2017029408A1 (en) * | 2015-08-20 | 2017-02-23 | Ratiopharm Gmbh | Solid state forms of sofosbuvir |
EP3430023A1 (en) | 2016-03-17 | 2019-01-23 | Mylan Laboratories, Limited | Polymorphic forms of sofosbuvir |
CZ2016257A3 (cs) | 2016-05-05 | 2017-11-15 | Zentiva, K.S. | Amorfní forma sofosbuviru, způsob její přípravy a její stabilizace |
BR102017011025A2 (pt) | 2016-06-02 | 2017-12-19 | Gilead Pharmasset Llc | Formulation of combination of three antiviral compounds |
US20190185507A1 (en) | 2016-08-19 | 2019-06-20 | Sandoz Ag | Sofosbuvir Derivatives for the Treatment of Hepatitis C |
CN108084237A (zh) * | 2016-11-23 | 2018-05-29 | 广东东阳光药业有限公司 | 索非布韦的一水合物及其制备方法 |
CN109952307B (zh) * | 2016-12-22 | 2022-03-25 | 四川科伦博泰生物医药股份有限公司 | 4’-硫代-2’-氟代核苷磷酰胺化合物的固体形式及其制备方法和用途 |
RU2656228C9 (ru) * | 2017-06-13 | 2019-04-16 | Олег Ростиславович Михайлов | Слабозакристаллизованная β-модификация (S)-изопропил 2-((S)-(((2R,3R,4R,5R)-5-(2,4-диоксо-3,4-дигидропиримидин-(2Н)-ил)-4-фтор-3-гидрокси-4-метилтетрагидрофуран-2-ил)метокси)-(фенокси)фосфориламино)пропаноата, способ её получения и фармацевтическая композиция на её основе |
WO2019025600A1 (en) | 2017-08-03 | 2019-02-07 | Sandoz Ag | SOFOSBUVIR HYDRATE |
EP3706762A4 (en) | 2017-12-07 | 2021-09-01 | Emory University | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTIVIRAL USES IN RELATION TO IT |
CN109517018B (zh) * | 2018-12-29 | 2021-05-04 | 石药集团中奇制药技术(石家庄)有限公司 | 一种索磷布韦新晶型及其制备方法 |
RU2745293C1 (ru) * | 2019-12-26 | 2021-03-23 | Общество С Ограниченной Ответственностью "Технология Лекарств" | Способ получения кристаллической формы 8 софосбувира (варианты) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
JP5582662B2 (ja) | 2009-05-13 | 2014-09-03 | ギリアード サイエンシーズ, インコーポレイテッド | 抗ウイルス化合物 |
US8618076B2 (en) * | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
TWI576352B (zh) * | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
CN104017020B (zh) * | 2010-03-31 | 2017-04-12 | 吉利德制药有限责任公司 | 核苷氨基磷酸酯 |
WO2011123654A1 (en) | 2010-04-02 | 2011-10-06 | Colucid Pharmaceuticals, Inc. | Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
AR091279A1 (es) | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
US10034893B2 (en) * | 2013-02-01 | 2018-07-31 | Enanta Pharmaceuticals, Inc. | 5, 6-D2 uridine nucleoside/tide derivatives |
-
2014
- 2014-12-04 TW TW103142194A patent/TW201609785A/zh unknown
- 2014-12-08 US US14/563,639 patent/US9340568B2/en not_active Expired - Fee Related
- 2014-12-08 CA CA2934799A patent/CA2934799A1/en not_active Abandoned
- 2014-12-08 BR BR112016013714A patent/BR112016013714A8/pt not_active IP Right Cessation
- 2014-12-08 AU AU2014370299A patent/AU2014370299B2/en not_active Ceased
- 2014-12-08 WO PCT/US2014/069123 patent/WO2015099989A1/en active Application Filing
- 2014-12-08 EA EA201691029A patent/EA201691029A1/ru unknown
- 2014-12-08 JP JP2016560620A patent/JP2017503015A/ja active Pending
- 2014-12-08 MX MX2016008453A patent/MX2016008453A/es unknown
- 2014-12-08 CN CN201480070460.XA patent/CN105873593A/zh active Pending
- 2014-12-08 AP AP2016009254A patent/AP2016009254A0/en unknown
- 2014-12-08 KR KR1020167019760A patent/KR20160099710A/ko not_active Application Discontinuation
- 2014-12-08 MY MYPI2016702283A patent/MY178102A/en unknown
- 2014-12-08 CR CR20160288A patent/CR20160288A/es unknown
- 2014-12-08 PE PE2016000813A patent/PE20160750A1/es unknown
- 2014-12-08 EP EP14819226.3A patent/EP3086795A1/en not_active Withdrawn
- 2014-12-08 MD MDA20160087A patent/MD20160087A2/ru not_active Application Discontinuation
- 2014-12-08 SG SG11201604818SA patent/SG11201604818SA/en unknown
- 2014-12-08 PH PH12019500372A patent/PH12019500372A1/en unknown
- 2014-12-22 AR ARP140104873A patent/AR098929A1/es unknown
- 2014-12-23 UY UY0001035917A patent/UY35917A/es not_active Application Discontinuation
-
2016
- 2016-06-06 IL IL246066A patent/IL246066A0/en unknown
- 2016-06-15 DO DO2016000141A patent/DOP2016000141A/es unknown
- 2016-06-15 CL CL2016001509A patent/CL2016001509A1/es unknown
- 2016-06-20 PH PH12016501203A patent/PH12016501203B1/en unknown
- 2016-06-22 CU CUP2016000096A patent/CU20160096A7/es unknown
- 2016-06-23 MX MX2019005253A patent/MX2019005253A/es unknown
- 2016-06-27 ZA ZA2016/04345A patent/ZA201604345B/en unknown
- 2016-09-06 HK HK16110590.5A patent/HK1222334A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
MX2016008453A (es) | 2016-10-14 |
JP2017503015A (ja) | 2017-01-26 |
PE20160750A1 (es) | 2016-07-27 |
AR098929A1 (es) | 2016-06-22 |
BR112016013714A8 (pt) | 2020-05-26 |
AU2014370299A1 (en) | 2016-06-23 |
DOP2016000141A (es) | 2016-07-15 |
AP2016009254A0 (en) | 2016-06-30 |
UY35917A (es) | 2015-05-29 |
MX2019005253A (es) | 2019-08-05 |
AU2014370299B2 (en) | 2017-11-30 |
CA2934799A1 (en) | 2015-07-02 |
ZA201604345B (en) | 2017-11-29 |
US9340568B2 (en) | 2016-05-17 |
TW201609785A (zh) | 2016-03-16 |
KR20160099710A (ko) | 2016-08-22 |
US20150175646A1 (en) | 2015-06-25 |
EP3086795A1 (en) | 2016-11-02 |
IL246066A0 (en) | 2016-07-31 |
SG11201604818SA (en) | 2016-07-28 |
CL2016001509A1 (es) | 2016-12-02 |
PH12019500372A1 (en) | 2020-03-02 |
HK1222334A1 (zh) | 2017-06-30 |
MY178102A (en) | 2020-10-02 |
CU20160096A7 (es) | 2016-11-29 |
PH12016501203A1 (en) | 2016-08-15 |
CR20160288A (es) | 2016-08-31 |
MD20160087A2 (ru) | 2016-12-31 |
CN105873593A (zh) | 2016-08-17 |
BR112016013714A2 (pt) | 2017-08-08 |
WO2015099989A1 (en) | 2015-07-02 |
PH12016501203B1 (en) | 2016-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201691029A1 (ru) | Кристаллические формы аналогов противовирусного соединения софосбувира | |
CY1123661T1 (el) | Κρυσταλλικη μορφη ενος αναστολεα της mdm2 | |
RS54368B1 (en) | CRYSTAL (S) -ISOPROPYL 2 - ((((S) - ((((2R, 3R, 4R, 5R) -5- (2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1- (2H) -IL) - 4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-IL) METOXY) (PHENOXY) PHOSPHORYL) AMINO) PROPANOATE | |
EA201592126A1 (ru) | 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b | |
EA201590943A1 (ru) | Замещенные нуклеозиды, нуклеотиды и их аналоги | |
PH12018500263A1 (en) | Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents | |
EA201391264A1 (ru) | 1'-замещенные пиримидиновые n-нуклеозидные аналоги для противовирусного лечения | |
EA201690473A1 (ru) | Комбинированный состав двух противовирусных соединений | |
EA201592075A1 (ru) | Замещенные нуклеозиды, нуклеотиды и их аналоги | |
IN2014MN02658A (ru) | ||
PH12017501598A1 (en) | �-D-2`-DEOXY-2`a-FLUORO-2`-�-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | |
EA201592082A1 (ru) | 3,4-дигидроизохинолин-2(1h)-ильные соединения | |
EA201691216A1 (ru) | Композиции линаклотида с замедленным высвобождением | |
EA201592081A1 (ru) | СОЕДИНЕНИЯ НА ОСНОВЕ МИКРО-РНК И СПОСОБЫ МОДУЛИРОВАНИЯ АКТИВНОСТИ miR-122 | |
EA201592184A1 (ru) | 4'-фтор-2'-метилзамещенные нуклеозидные производные | |
EA200901080A1 (ru) | Новые нуклеозидные аналоги для лечения вирусных инфекций | |
EA201490213A1 (ru) | Бензофурановые соединения для лечения инфекций вирусом гепатита с | |
EA201590770A1 (ru) | Ингибиторы вируса гепатита с | |
WO2014152716A8 (en) | Substituted heterocyclic compounds for treating or preventing viral infections | |
EA201400282A1 (ru) | Сокристаллы ципродинила и дитианона | |
EA201492256A1 (ru) | Пролекарства 5-(5-фенил-4-(пиридин-2-илметиламино)хиназолин-2-ил)пиридин-3-сульфонамида на основе фосфорамидной кислоты | |
EA201590006A1 (ru) | Комбинация терапевтических средств для лечения инфекции, вызванной вирусом гепатита c | |
ATE509945T1 (de) | Chirale mit phosphonsäureester- oder phosphonsäure- substituierte verbindungen | |
BR112015023591A2 (pt) | processo para a preparação de 4-amino-1-((ls,4r,5s)-2-fluoro-4,5-di-hidróxi-3-hidroximetil-ciclopent-2-enii)-1h-pirimidin-2-ona | |
UA111951C2 (uk) | Заміщені аналоги нуклеотидів |